Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant fibrinogen variant (MRSA host-defense)
- Development stage
- Preclinical
- Lead developer
- Fibriant
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
This recombinant fibrinogen variant is a preclinical-stage engineered protein developed by Fibriant for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Unlike traditional antibiotics, this specific variant (identified as fibrinogen γ′-γ′) utilizes host-defense properties to improve survival in systemic infection models. The protein is produced using a proprietary recombinant manufacturing platform involving Chinese hamster ovary (CHO) cell expression technology. Research indicates that the engineered variant enhances the host's innate immune response and clotting-related defense mechanisms against S. aureus, rather than exerting direct antimicrobial activity. In animal models of bacteremia, the drug is administered systemically, typically via intravenous injection.
- Other names
- fibrinogen γ′-γ′recombinant fibrinogen variantMRSA host-defense fibrinogen
Beyond the preview
Go deeper on recombinant fibrinogen variant (MRSA host-defense).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant fibrinogen variant (MRSA host-defense).